Effects of aclidinium on determinants of COPD severity: symptoms and quality of life

References

• GBD Global Burden of Disease Study 2013 CollaboratorsGlobal, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013Lancet2015386999574380026063472
   PubMed Web of Science ®Google Scholar
• VestboJHurdSSAgustiAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2013187434736522878278
   PubMed Web of Science ®Google Scholar
• GavaldaARamosICarcasonaCThe in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromidePulm Pharmacol Ther201428211412124928173
   PubMed Web of Science ®Google Scholar
• GavaldaAMiralpeixMRamosICharacterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profileJ Pharmacol Exp Ther2009331274075119710368
   PubMed Web of Science ®Google Scholar
• AgustiACalverleyPMCelliBCharacterisation of COPD heterogeneity in the ECLIPSE cohortRespir Res20101112220831787
   PubMed Web of Science ®Google Scholar
• LangePMarottJLVestboJPrediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general populationAm J Respir Crit Care Med20121861097598122997207
   PubMed Web of Science ®Google Scholar
• BestallJCPaulEAGarrodRGarnhamRJonesPWWedzichaJAUsefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary diseaseThorax199954758158610377201
   PubMed Web of Science ®Google Scholar
• GOLD Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonart Diesase (updated 2015), 2015 Available from: www.goldcopd.org/Accessed August, 2015
   Google Scholar
• KesslerRPartridgeMRMiravitllesMSymptom variability in patients with severe COPD: a pan-European cross-sectional studyEur Respir J201137226427221115606
   PubMed Web of Science ®Google Scholar
• PartridgeMRKarlssonNSmallIRPatient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet surveyCurr Med Res Opin20092582043204819569976
   PubMed Web of Science ®Google Scholar
• PriceDSmallMMilliganGHigginsVGilEGEstruchJImpact of night-time symptoms in COPD: a real-world study in five European countriesInt J Chron Obstruct Pulmon Dis2013859560324348032
   PubMed Web of Science ®Google Scholar
• ValipourALaviePLothallerHMikulicIBurghuberOCSleep profile and symptoms of sleep disorders in patients with stable mild to moderate chronic obstructive pulmonary diseaseSleep Med201112436737221388878
   PubMed Web of Science ®Google Scholar
• AgustiAHednerJMarinJMBarbeFCazzolaMRennardSNight-time symptoms: a forgotten dimension of COPDEur Respir Rev20112012118319421881146
   PubMedGoogle Scholar
• CordaLNovaliMMontemurroLTPredictors of nocturnal oxyhemoglobin desaturation in COPDRespir Physiol Neurobiol20111792–319219721864725
   PubMed Web of Science ®Google Scholar
• OwensRLMalhotraASleep-disordered breathing and COPD: the overlap syndromeRespir Care2010551013331344 discussion 1344–133620875160
   PubMed Web of Science ®Google Scholar
• KwonJSWolfeLFLuBSKalhanRHyperinflation is associated with lower sleep efficiency in COPD with co-existent obstructive sleep apneaCOPD20096644144519938967
   PubMedGoogle Scholar
• LangePMarottJLVestboJNordestgaardBGPrevalence of night-time dyspnoea in COPD and its implications for prognosisEur Respir J20144361590159824488571
   PubMed Web of Science ®Google Scholar
• PickardASYangYLeeTAComparison of health-related quality of life measures in chronic obstructive pulmonary diseaseHealth Qual Life Outcomes201192621501522
   PubMed Web of Science ®Google Scholar
• Domingo-SalvanyALamarcaRFerrerMHealth-related quality of life and mortality in male patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2002166568068512204865
   PubMed Web of Science ®Google Scholar
• JonesPWBrusselleGDal NegroRWHealth-related quality of life in patients by COPD severity within primary care in EuropeRespir Med20111051576620932736
   PubMed Web of Science ®Google Scholar
• JonesPWQuirkFHBaveystockCMLittlejohnsPA self-complete measure of health status for chronic airflow limitation. The St George’s Respiratory QuestionnaireAm Rev Respir Dis19921456132113271595997
   PubMed Web of Science ®Google Scholar
• WeatherallMMarshSShirtcliffePWilliamsMTraversJBeasleyRQuality of life measured by the St George’s Respiratory Questionnaire and spirometryEur Respir J20093351025103019164350
   PubMed Web of Science ®Google Scholar
• JonesPWHardingGBerryPWiklundIChenWHKline LeidyNDevelopment and first validation of the COPD Assessment TestEur Respir J200934364865419720809
   PubMed Web of Science ®Google Scholar
• MiravitllesMWorthHSoler CatalunaJJObservational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS studyRespir Res20141512225331383
   PubMed Web of Science ®Google Scholar
• RabeKFHurdSAnzuetoAGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2007176653255517507545
   PubMed Web of Science ®Google Scholar
• SantusPRadovanovicDHenchiSAssessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patientsRespir Physiol Neurobiol2014197364524726342
   PubMed Web of Science ®Google Scholar
• SantusPCentanniSVergaMDi MarcoFMateraMGCazzolaMComparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflationRespir Med200610071277128116337781
   PubMed Web of Science ®Google Scholar
• JonesPWSinghDBatemanEDEfficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN studyEur Respir J201240483083622441743
   PubMed Web of Science ®Google Scholar
• KerwinEMD’UrzoADGelbAFLakkisHGarcia GilECaractaCFEfficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I)COPD2012929010122320148
   PubMedGoogle Scholar
• D’UrzoAKerwinERennardSHeTGilEGCaractaCOne-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPDCOPD201310450051023679347
   PubMedGoogle Scholar
• GelbAFTashkinDPMakeBJZhongXGarcia GilECaractaCLong-term safety and efficacy of twice-daily aclidinium bromide in patients with COPDRespir Med2013107121957196523916502
   PubMed Web of Science ®Google Scholar
• SantusPRadovanovicDDi MarcoFRaccanelliRValentiVCentanniSFaster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized cross-over studyPulm Pharmacol Ther201535424926549785
   PubMed Web of Science ®Google Scholar
• ScichiloneNBenfanteABocchinoMWhich factors affect the choice of the inhaler in chronic obstructive respiratory diseases?Pulm Pharmacol Ther201531636725724817
   PubMed Web of Science ®Google Scholar
• LaubeBLJanssensHMde JonghFHWhat the pulmonary specialist should know about the new inhalation therapiesEur Respir J20113761308133121310878
   PubMed Web of Science ®Google Scholar
• BlasiFCanonicaGWCentanniSGenuair® usability test: results of a National Public Survey of the ElderlyCOPD201513336737126645660
   PubMedGoogle Scholar
• IsmailaASHuismanELPunekarYSKarabisAComparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysisInt J Chron Obstruct Pulmon Dis2015102495251726604738
   PubMed Web of Science ®Google Scholar
• FuhrRMagnussenHSaremKEfficacy of aclidinium bromide 400 mug twice daily compared with placebo and tiotropium in patients with moderate to severe COPDChest2012141374575221903737
   PubMed Web of Science ®Google Scholar
• BeierJKirstenAMMrozREfficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb studyCOPD201310451152223819698
   PubMedGoogle Scholar
• D’UrzoAFergusonGTvan NoordJAEfficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialRespir Res20111215622151296
   PubMed Web of Science ®Google Scholar
• PleasantsRAWangTGaoJTangHDonohueJFInhaled umeclidinium in COPD patients: a review and meta-analysisDrugs201676334336126755180
   PubMed Web of Science ®Google Scholar
• ManninoDMDohertyDESonia BuistAGlobal Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) studyRespir Med2006100111512215893923
   PubMed Web of Science ®Google Scholar
• FigarskaSMBoezenHMVonkJMDyspnea severity, changes in dyspnea status and mortality in the general population: the Vlagtwedde/Vlaardingen studyEur J Epidemiol2012271186787623054033
   PubMed Web of Science ®Google Scholar
• NiHSoeZMoeSAclidinium bromide for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev20149CD010509
   Google Scholar